Chris Eso, VP of Strategy, Growth and Business Development, Medtronic
Chris Eso is Vice President of Corporate Development for Medtronic, specifically covering the Cardiac and Vascular Group business units, including Cardiac Rhythm and Heart Failure (CRHF), Coronary and Structure Heart (CSH), and Aortic, Peripheral Vascular and endoVenous (APV). Chris joined Medtronic as the Senior Manager of Business Development in August of 2011. He oversaw Medtronic’s global inorganic growth strategies and opportunities for Coronary business, and was promoted in June of 2012 to expand his Business Development responsibilities to include the Renal Denervation business. In April of 2013, Chris was promoted to Director, overseeing Business Development functions and leading a team of professionals. In September of 2014, Chris was promoted to Senior Director, Business Development for the Coronary and Structural Heart business unit for Medtronic, and in February of 2016, Chris was promoted to Vice President of Corporate Development.
Chris has more than 18 years of successful professional experience, of increasing responsibilities, with the majority of his experience in a business/corporate development and strategy capacity within the pharmaceutical and medical device industries, in addition to Medtronic, including Allergan, Watson, Agilent Technologies and Peregrine Pharmaceuticals, where he was Vice President of Business Operations.
Chris holds an MBA from Concordia University and BA in Public Relations, Communications from California State University, Fullerton.